Ennovabio (Zhejiang) Pharmaceuticals Co. Ltd. and Shanghai Ennova Biopharmaceutical Co. Ltd. have described 5-membered and 6-membered heterocyclic compounds acting as non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of cancer, viral infection, transplant rejection, cardiovascular and inflammatory disorders, and autoimmune, myeloproliferative and metabolic diseases.